Eli Lilly and Company Stock Borsa Italiana

Equities

4LLY

US5324571083

Pharmaceuticals

Real-time Estimate Tradegate 08:39:00 2024-07-17 am EDT 5-day change 1st Jan Change
832.4 EUR -4.77% Intraday chart for Eli Lilly and Company +2.14% +66.00%
Sales 2024 * 42.99B 39.31B Sales 2025 * 52.8B 48.29B Capitalization 848B 775B
Net income 2024 * 11.93B 10.91B Net income 2025 * 16.68B 15.25B EV / Sales 2024 * 20.2 x
Net Debt 2024 * 20.24B 18.5B Net Debt 2025 * 16.14B 14.76B EV / Sales 2025 * 16.4 x
P/E ratio 2024 *
70.4 x
P/E ratio 2025 *
50.3 x
Employees 43,000
Yield 2024 *
0.55%
Yield 2025 *
0.64%
Free-Float 99.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.67%
1 week+2.14%
Current month+2.80%
1 month+6.12%
3 months+24.40%
6 months+47.76%
Current year+66.00%
More quotes
1 week
859.30
Extreme 859.3
883.20
1 month
822.60
Extreme 822.6
883.20
Current year
529.50
Extreme 529.5
883.20
1 year
400.20
Extreme 400.2
883.20
3 years
193.50
Extreme 193.5
883.20
5 years
105.00
Extreme 105
883.20
10 years
105.00
Extreme 105
883.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 56 95-12-31
President - -
Chief Tech/Sci/R&D Officer - 23-10-15
Members of the board TitleAgeSince
Director/Board Member 63 21-01-24
Director/Board Member 68 09-03-31
Director/Board Member 64 04-12-31
More insiders
Date Price Change Volume
24-07-15 874 +0.33% 120
24-07-15 871.1 +0.32% 46
24-07-12 868.3 +1.69% 16
24-07-11 853.9 -1.76% 19
24-07-10 869.2 +1.58% 52

End-of-day quote Borsa Italiana, July 15, 2024

More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
941.6 USD
Average target price
901.5 USD
Spread / Average Target
-4.26%
Consensus
1st Jan change Capi.
+32.75% 627B
-3.66% 363B
+15.06% 318B
+9.18% 299B
+13.48% 243B
+16.37% 225B
+15.67% 179B
+2.47% 167B
+1.53% 125B
Other Pharmaceuticals